Interestingly, CPH has been identified as potent Setd7 inhibitor with anti-tumor properties in various cancer types, including hepatocellular carcinoma, myeloma, leukemia, mantle cell lymphoma, breast cancer, and urothelial carcinoma by inducing apoptosis and cell cycle arrest [6–8], inhibiting histone deacetylase [9], estrogen receptor alpha [10], mTOR and β-catenin signaling pathways [11], and restoring epigenetic silencing of IRF6 [6–9, 11, 12]. Here, SETD7 is linked to breast carcinoma.